Both ClpP agonists and POLRMT inhibitors inhibit mitochondrial transcription, deplete mtDNA, impair OXPHOS, and are potentially disruptive to multiple aspects of cancer cell metabolism, making them distinct from other mitochondrial targeted approaches (i.e., metformin, CPI-613, etc.)(Figure 6). Here, CLPP is linked to cancer.